Form 4: Kymera Therapeutics Director Sells Shares

Kymera Therapeutics Director Bruce Booth reported the sale of common stock valued at over $350 million through a Rule 10b5-1 trading plan.

Summary

• Bruce Booth, a Director at Kymera Therapeutics, Inc., reported the sale of a significant number of common shares on June 25, 2026.
• The transactions were executed under a Rule 10b5-1 trading plan adopted on December 11, 2025.
• The sales involved multiple tranches with weighted average prices ranging from $119.08 to $130.05.
• The total value of the reported sales exceeds $350 million.
• The shares sold were held by entities associated with Booth, specifically Atlas Venture Fund X, L.P. and Atlas Venture Opportunity Fund I, L.P., with Booth disclaiming beneficial ownership beyond his pecuniary interest.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this as a negative sentiment due to the significant volume of shares sold by a director, despite being executed under a 10b5-1 plan.

Negatives

• A significant number of shares were sold by a company director, potentially signaling a lack of confidence or a need for liquidity by the insider.
• The total value of shares sold is substantial, which could be interpreted negatively by the market.

Risks

• The sale of a large number of shares by a director could be perceived as a negative signal by investors, potentially impacting the stock price.
• While executed under a 10b5-1 plan, the sheer volume of the sale might raise questions about the director's conviction in the company's future prospects.

Future Outlook

The filing itself does not contain forward-looking statements or guidance regarding the company's future performance. It solely reports on past transactions.

Management Comments

• The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold each separate price within the ranges set forth in footnotes (2) and (4) through (13).
• Bruce Booth is a member of AVA X LLC and AVAO LLC and disclaims Section 16 beneficial ownership of the securities held by Atlas Venture Fund X and Atlas Venture Opportunity Fund I, L.P., respectively, except to the extent of his pecuniary interest therein, if any.

Industry Context

StockSavvy.ai notes that insider selling, even under a pre-arranged 10b5-1 plan, can be a sensitive indicator for investors in the biotechnology sector, where stock prices can be highly volatile and influenced by clinical trial results and regulatory approvals. Significant sales by directors may lead to increased scrutiny.

Related Party Transactions

• The sales were conducted by entities (Atlas Venture Fund X, L.P. and Atlas Venture Opportunity Fund I, L.P.) where Bruce Booth has a relationship as a member of the general partner's management entities, and he disclaims beneficial ownership beyond his pecuniary interest.

Stakeholder Impact

• Shareholders may view the large sale by a director negatively, potentially leading to short-term stock price pressure.
• Employees and creditors are unlikely to be directly impacted by this specific transaction, but any significant negative market reaction could indirectly affect morale and financial standing.

Next Steps

• The reporting person may be required to provide further details upon request from the SEC, security holders, or the Issuer regarding the specific prices of shares sold within the reported ranges.

Key Dates

Recommendation

While the sale by a director is a negative signal, it was executed under a pre-established 10b5-1 plan, suggesting it was planned in advance and not necessarily a reaction to new negative information. Without further context on the company's performance or the director's reasons for the sale, a 'hold' recommendation is prudent, advising investors to monitor future filings and company news.

Keywords

Kymera Therapeutics, KYMR, Form 4, Insider Trading, Stock Sale, Bruce Booth, Rule 10b5-1, Director Sale, Beneficial Ownership